// App-Quantinova.ai

1655 : Carfilzomib 56mg/m2 Twice-Weekly in Combination with Dexamethasone and Daratumumab (KdD) Versus Daratumumab in Combination with 8 Cycles of Bortezomib and Dexamethasone (DVd); A Matching-Adjusted Indirect Treatment Comparison

Researchers

Presenter

  • Katja Weisel

Principal Investigators

  • Ajay Nooka

  • Evangelos Terpos

  • Andrew Spencer

  • Hartmut Goldschmidt

  • Istvan Majer

  • Lucy DeCosta

  • Rohan Medhekar

  • Akeem Yusuf

  • Shaji K. Kumar

Medical Centers

  • Department of Neurosurgery, University Medical Center Hamburg-Eppendorf, Hamburg, Germany

  • Winship Cancer Institute, Department of Hematology and Medical Oncology, Emory University, Atlanta, GA

  • Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Alexandra General Hospital, Athens, Greece

  • Australian Centre for Blood Diseases, Myeloma Research Group, Alfred Hospital, Monash University, Melbourne, Australia

  • Department of Internal Medicine V and National Centre for Tumor Diseases, University of Heidelberg, Heidelberg, Germany

  • Economic Modeling CoE, Pricing and Access CoE, Global Value and Access, Amgen (Europe) GmbH, Rotkreuz, Switzerland

  • Global Biostatistical Science, Amgen Ltd, Uxbridge, United Kingdom

  • Amgen Inc, Thousand Oaks, CA

  • Division of Medical Oncology, Mayo Clinic, Rochester, MN

Locations

  • Germany

  • United States

  • Greece

  • Australia

  • Switzerland

  • United Kingdom

Companies

  • Amgen Inc.

Study Components

Therapeutic Area

  • N/A

Disease

  • N/A

Biomarkers

  • N/A

Drug/Treatment

  • Dexamethasone

  • Dekpak 13 Day Taperpak

  • carfilzomib Intravenous

  • daratumumab Intravenous

  • Bortezomib

Outcome

  • N/A

Study Design

  • N/A

Phase

  • III

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved